Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Joyce O’Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; and Paolo Tarantino, MD, PhD; discuss results of recent frontline maintenance trials for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) and their implications for treatment sequencing and patient management.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess emerging clinical evidence supporting current and novel treatment strategies in the frontline setting for HER2+ MBC
• Develop individually tailored induction and maintenance regimens based on patient and disease characteristics

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Pfizer, Inc.

Chair:

Joyce O’Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX

Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GSK, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily

Faculty:

Reshma L. Mahtani, DO

Medical Oncologist
Chief of Breast Medical Oncology
Baptist Health Miami Cancer Institute
Miami, FL

Disclosures: Consultant: Agendia, Arvinas, AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Hologic, Lilly, Novartis, Pfizer, Sermonix, Stemline; Grant/Research Support: Gilead Sciences

Heather McArthur, MD, MPH

Professor of Internal Medicine Clinical
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, TX

Disclosures: Consultant: Amgen, Arvinas, AstraZeneca, Bristol Myers Squibb, Calithera, Celgene, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Peregrine, Pfizer, Puma, Spectrum Pharmaceuticals, Seattle Genetics, Syndax Pharmaceuticals, TapImmune; Grant/Research Support: Bristol Myers Squibb, BTG, MedImmune/AstraZeneca, Merck

Paolo Tarantino, MD, PhD

Clinical Fellow Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Menarini/Stemline, Novartis, Roche; Grant/Research Funding: AstraZeneca

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by an AI tool.

To learn more about this topic, including information on first-line induction options, evolving treatment algorithms, and ongoing trials for HER2+ MBC, go to https://www.gotoper.com/mbcc26maintenance-activity.

Release Date

April 10, 2026

Expiration Date

April 10, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.